New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:02 EDTAFFXAffymetrix receives clearance to market CytoScan Dx Assay
Affymetrix announced that it has received 510k clearance from the FDA to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children’s developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.
News For AFFX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
06:06 EDTAFFXAffymetrix announces Chairman and Founder Stephen Fodor to retire from board
Affymetrix announced that Founder and Chairman, Stephen Fodor will retire from the company’s board effective January 30, 2015. The board elected Jami Nachtsheim as Chairwoman of the company’s board, succeeding Fodor. Nachtsheim has served as a director of the company since 2010 and the company’s lead independent director since 2013.
January 21, 2015
10:01 EDTAFFXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:21 EDTAFFXAffymetrix downgraded to Neutral from Outperform at RW Baird
Baird downgraded Affymetrix to Neutral from Outperform citing reduced risk/reward. Baird maintains its $11 price target on Affymetrix shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use